Actualités et Activités de Clearside Biomedical
Présence
Clearside Biomedical est une société cotée sous le symbole boursier CLSD (US).
Dirigeants
Voir l'organigramme avec ses 18 principaux dirigeants
Biographies les plus recherchées chez Clearside Biomedical
- George Lasezkay, Chief Executive Officer and Director
- William Humphries, Director
- Clay Thorp, Director
Changements de dirigeants chez Clearside Biomedical
- Anthony Gibney qui était Director, est promu Chairman of the Board (publié le 5 novembre 2024).
Créer une alerte
pour suivre les mouvements de dirigeants chez Clearside Biomedical.
Biotechnologie
Clearside Biomedical a 2 350 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Genus (Royaume—Uni).
Actualités en fusion/acquisition en Biotechnologie.
- Transcarent and Accolade have merged (publié le 9 avril 2025)..
- Kashiv BioSciences vient d'annoncer une levée de fonds de 150 millions de dollars. (publié le 7 avril 2025).
- Atsena Therapeutics vient d'annoncer une levée de fonds de 150 millions de dollars. (publié le 4 avril 2025).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Clearside Biomedical
- Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program | Clearside Biomedical, Inc.- IR Site
- Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore | Clearside Biomedical, Inc.- IR Site
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Clearside Biomedical
- Clearside Biomedical sur Wikipédia, Google News & Yahoo Finance en 1-click
- Clearside Biomedical sur LinkedIn, Twitter & YouTube en 1-click
